naa a22 4500 510779913 CHVBK 20180411083243.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s11892-013-0404-x doi (NATIONALLICENCE)springer-10.1007/s11892-013-0404-x Unger Jeff Unger Primary Care, 14726 Ramona Ave, Suite 110, 91710, Chino, CA, USA aut Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes [Elektronische Daten] [Jeff Unger] Clinicians and patients are rapidly adapting GLP-1 receptor agonists as efficacious and safe therapeutic options for managing type 2 diabetes (T2DM). GLP-1 receptor agonists stimulate insulin production and secretion from the pancreatic β cells in a glucose-dependent manner, improve gastric emptying, favor weight reduction, and reduce postabsorptive glucagon secretion from pancreatic α cells. GLP-1 receptor activity is impaired in patients with T2DM. GLP-1 secretion and subsequent physiologic actions in patients with type 1 diabetes (T1DM) is ill-defined. Some researchers have suggested that the use of GLP-1 receptor agonists in T1DM may reduce excessive postprandial glucagon secretion allowing patients to reduce their total daily dose of exogenous insulin. Hypoglycemia risk may also be minimized in T1DM as glucagon counter-regulation can be preserved to some degree via the glucose-dependent action of the GLP-1 receptor agonists. This paper will consider the physiologic and pharmacologic benefits of adding GLP-1 receptor agonists to therapeutic regimens of patients with T1DM. Springer Science+Business Media New York, 2013 GLP-1 receptor agonists nationallicence Type 1 diabetes nationallicence Hyperglucagonemia nationallicence Liraglutide nationallicence Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 663-668 1534-4827 13:5<663 2013 13 11892 https://doi.org/10.1007/s11892-013-0404-x text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0404-x text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Unger Jeff Unger Primary Care, 14726 Ramona Ave, Suite 110, 91710, Chino, CA, USA aut NATIONALLICENCE 773 0- Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 663-668 1534-4827 13:5<663 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer